Systemic immunomodulatory therapies in severe atopic dermatitis: a comprehensive review of mechanisms, efficacy and long-term management stratagems
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20261940Keywords:
Atopic dermatitis, Severe systemic therapy, Biologics, Dupilumab, JAK inhibitors, Interleukin antagonists, Immunomodulation, Treatment guidelines, Real-world evidence, Precision dermatologyAbstract
Severe atopic dermatitis (AD) represents a complex, chronic inflammatory dermatosis characterized by a profoundly debilitating course, significant comorbid burden and a substantial deterioration in quality of life. The pathophysiological paradigm has evolved beyond a purely T-helper 2 (Th2)-centric model to incorporate a broader spectrum of immune dysregulation, including roles for Th22, Th17 and IL-31-driven pathways, alongside crucial epithelial barrier dysfunction mediated by filaggrin and other structural protein deficiencies. This shift has catalyzed the development and clinical deployment of novel, targeted systemic agents that move beyond traditional immunosuppressants. This exhaustive review synthesizes contemporary evidence from recent clinical trials, real-world efficacy studies and international consensus guidelines to critically appraise the current therapeutic arsenal. We provide a detailed analysis of the pharmacodynamics, clinical trial data and safety profiles for biologic agents such as dupilumab, tralokinumab and lebrikizumab, which selectively inhibit key interleukins. Furthermore, we examine the emerging role of Janus kinase (JAK) inhibitors, including abrocitinib, upadacitinib and baricitinib, focusing on their rapid onset of action and the nuanced risk-benefit calculus mandated by their safety advisories. The review also contextualizes the enduring, though carefully circumscribed, role of conventional systemic immunosuppressants like cyclosporine, methotrexate and mycophenolate mofetil in the modern treatment algorithm. Particular emphasis is placed on therapeutic sequencing, combination approaches, management of secondary infections and strategies for long-term disease control while mitigating adverse effects. The concluding synthesis projects future directions, including combination biologic therapy and personalized medicine approaches guided by endotypic stratification, underscoring the transformative nature of current systemic treatments in altering the disease trajectory for patients with severe atopic dermatitis.
References
Drucker AM, Ellis A, Jabbar-Lopez Z, Ahmad A, Anstey AV, Flohr C, et al. Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. BMJ Open. 2018;8(8):e023061. DOI: https://doi.org/10.1136/bmjopen-2018-023061
Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Silverberg JI, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659-67. DOI: https://doi.org/10.1001/jamadermatol.2020.0796
Drucker AM, Morra DE, Prieto-Merino D, Yiu ZZN, Abuabara K, Silverberg JI, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523-32. DOI: https://doi.org/10.1001/jamadermatol.2022.0455
Drucker AM, Lam M, Elsawi R, Prieto-Merino D, Malek R, Ellis AG, et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2024;190(2):184-90. DOI: https://doi.org/10.1093/bjd/ljad393
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777-84. DOI: https://doi.org/10.7326/M14-2385
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. DOI: https://doi.org/10.1136/bmj.d5928
Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-49. DOI: https://doi.org/10.1016/j.jaad.2014.03.030
Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. PLoS Med. 2016;13(9):e1002127. DOI: https://doi.org/10.1371/journal.pmed.1002127
Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163-71. DOI: https://doi.org/10.1016/j.jclinepi.2010.03.016
Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RAC, Furukawa TA, Guyatt GH, et al. GRADE Working Group. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36-44. DOI: https://doi.org/10.1016/j.jclinepi.2017.10.005
Puhan MA, Schünemann HJ, Murad MH, Wang R, Holtmann G, Vist GE, et al. GRADE Working Group. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630. DOI: https://doi.org/10.1136/bmj.g5630
Johnston BC, Thorlund K, Schünemann HJ, Xie F, Guyatt GH, Higgins JPT, et al. Improving the interpretation of quality-of-life evidence in meta-analyses: the application of minimal important difference units. Health Qual Life Outcomes. 2010;8:116. DOI: https://doi.org/10.1186/1477-7525-8-116
Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99-106. DOI: https://doi.org/10.1111/j.1398-9995.2011.02719.x
Yosipovitch G, Reaney M, Mastey V, Fleischer AB, McCall C, Lebwohl M, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761-9. DOI: https://doi.org/10.1111/bjd.17744
Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27-33. DOI: https://doi.org/10.1159/000365390
Efficacy and Safety Study of QAW039 in the Treatment of Patients with Moderate to Severe Atopic Dermatitis. Bethesda (MD): ClinicalTrials.gov. 2013-2015. Identifier NCT01785602. Available at: https://clinicaltrials.gov/show/NCT01785602. Accessed on 04 February 2026.
Downloads
Published
How to Cite
Issue
Section
